The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, ByRoots Analysis

The recent approval of first RNAi therapeutic, ONPATTRO^TM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research

London

Roots Analysis has announced the addition of “RNAi Therapeutics Market (2^nd Edition), 2019-2030” report to its list of offerings.

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

Key Market Insights

Over 170 RNAi therapeutics are currently under development

Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.

More than 70% of ongoing clinical trials are being conducted in North America and Europe

In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.

RNAi therapeutics market is anticipated to increase at a CAGR of over 45% between 2019-2030

This growth is anticipated to be primarily driven by the target specificity of the drug candidates. North America (primarily the US) are expected to capture the majority share by 2030.

To request a sample copy / brochure of this report, please visit this – https://www.rootsanalysis.com/reports/278/request-sample.html

Key Questions Answered

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1. Gene Therapy Market (3^rd Edition), 2019-2030
2. Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4^th Edition), 2019-2030
3. Biopharma Contract Manufacturing Market (3^rd Edition), 2019-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/